Preparing for EU HTA Joint Clinical Assessments and Joint Scientific Consultations – Practical information to navigate the new procedures

22. Jan 2025 — Register here

From 12 January 2025 the EU HTA Regulation will apply and the first Joint Clinical Assessments (JCA) will be performed to assess the relative clinical effectiveness of new innovative cancer therapies and cell and gene therapies approved by the EMA. In just three years, by 13 January 2028, these joint assessments will also be performed for all new Orphan Medicinal Products (OMPs).

Get prepared ! Join our very own experts Alexander Natz and Matias Olsen on Wednesday 15 January, for a one-hour session starting at 15:00pm CET.
They will explain the final procedural rules that have been adopted in 2024 in the various Implementing Acts and walk you through the procedural steps and the practical guidance documents that have been adopted by the HTA Coordination Group. Participants are invited to ask questions and share their views through a dynamic Q&A session.

Don’t miss this chance to prepare for the new market launch requirements in Europe. Register now!

Find out ore about EUCOPE activities on EU HTA here